Encephalomyelitis Companies

Jan 2024Valneva SE Received positive Phase IIa clinical trial results for their investigational vaccine, Ixi-CMV, against cytomegalovirus (CMV) encephalitis, a common cause of encephalitis in immunocompromised individuals.Partnered with leading research institutions to develop new vaccines and diagnostic tools for diverse forms of encephalitis, including Japanese encephalitis and West Nile virus encephalitis.

Genentech (Roche) Received FDA approval for Actemra (tocilizumab) for treating pediatric patients with multisystem inflammatory syndrome in children (MIS-C), a condition sometimes associated with post-infectious encephalitis.Conducted research on combining Actemra with other immunomodulatory therapies for synergistic effects in managing severe cases of encephalitis with significant inflammatory components.

GlaxoSmithKline (GSK) Launched a global awareness campaign highlighting the importance of timely diagnosis and treatment of encephalitis, addressing the often-unfamiliar nature of this condition.Collaborated with healthcare providers to improve clinical guidelines and treatment protocols for different types of encephalitis, emphasizing personalized care and optimizing patient outcomes.

List of Encephalomyelitis Key Companies in the Market

• Bristol-Myers Squibb Company (U.S.)


• Sanofi (France)


• GlaxoSmithKline Plc. (U.K)


• Spectrum Pharmaceuticals Inc. (U.S.)


• Amgen, Inc. (U.S.)


• Merck & Co., Inc. (U.S.)


• Bayer AG (Germany)


• Novartis AG (Switzerland)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Eli Lilly and Company (U.S.)


• AstraZeneca Plc. (U.K)


• Janssen Biotech, Inc. (U.S.)


• AbbVie Inc. (U.S.)


• Takeda Pharmaceuticals (Japan)


• Immunomedics (U.S.)


• Pfizer, Inc. (U.S.)


• Oncomed Pharmaceuticals (U.S.)